Creating a Pathway Over the Regulatory Chasm: A Fresh Start

摘要

With the election over, a clear framework for guiding follow-on biologics to market may soon emerge. But difficult issues of cost, timing, and even terminology are keeping innovators and generic rivals on opposite sides of the fence.